These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 31727164)

  • 21. Association of Patient, Prescriber, and Region With the Initiation of First Prescription of Biologic Disease-Modifying Antirheumatic Drug Among Older Patients With Rheumatoid Arthritis and Identical Health Insurance Coverage.
    Tatangelo M; Tomlinson G; Paterson JM; Ahluwalia V; Kopp A; Gomes T; Bansback N; Bombardier C
    JAMA Netw Open; 2019 Dec; 2(12):e1917053. PubMed ID: 31808927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Golimumab for the treatment of psoriatic arthritis.
    Yang H; Epstein D; Bojke L; Craig D; Light K; Bruce I; Sculpher M; Woolacott N
    Health Technol Assess; 2011 May; 15 Suppl 1():87-95. PubMed ID: 21609657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study.
    Smolen JS; Gladman D; McNeil HP; Mease PJ; Sieper J; Hojnik M; Nurwakagari P; Weinman J
    RMD Open; 2019; 5(1):e000585. PubMed ID: 30713716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ALIGN PsA: Advancing a Multidisciplinary Approach in PsA.
    Baum EW; Schwartzman S
    Semin Cutan Med Surg; 2018 Dec; 37(6S):S125-S134. PubMed ID: 30605493
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
    Wu N; Lee YC; Shah N; Harrison DJ
    Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in US Veterans: Effect of Specialty Care and Geographic Distance.
    Walsh JA; Pei S; Burningham Z; Penmetsa G; Cannon GW; Clegg DO; Sauer BC
    J Rheumatol; 2018 Mar; 45(3):430-436. PubMed ID: 29142040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population.
    Michelsen B; Diamantopoulos AP; Høiberg HK; Soldal DM; Kavanaugh A; Haugeberg G
    J Rheumatol; 2017 Apr; 44(4):431-436. PubMed ID: 28148701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey.
    van de Kerkhof PC; Reich K; Kavanaugh A; Bachelez H; Barker J; Girolomoni G; Langley RG; Paul CF; Puig L; Lebwohl MG
    J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):2002-10. PubMed ID: 25885420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Barriers to providing adequate rheumatology care: implications from a survey of rheumatologists in ontario, Canada.
    Shipton D; Badley EM; Bookman AA; Hawker GA
    J Rheumatol; 2002 Nov; 29(11):2420-5. PubMed ID: 12415603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study.
    Queiro R; Cañete JD; Montilla C; Abad M; Montoro M; Gómez S; Cábez A;
    Arthritis Res Ther; 2017 Mar; 19(1):72. PubMed ID: 28356155
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treating psoriatic arthritis to target: discordance between physicians and patients' assessment, non-adherence, and restricted access to drugs precluded therapy escalation in a real-world cohort.
    Ferreira MF; Kohem CL; Xavier RM; Abegg E; Martins OS; Resmini MB; de Mello AL; de Almeida Menegat F; Hax V; Gasparin AA; Brenol CV; de Andrade NPB; Viecceli D; Brenol JCT; Palominos PE
    Clin Rheumatol; 2019 Mar; 38(3):961-968. PubMed ID: 30511296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor.
    Ogdie A; Palmer JL; Greenberg J; Curtis JR; Harrold LR; Solomon DH; Kavanaugh A; Kremer JM; Mease PJ
    J Rheumatol; 2019 May; 46(5):475-482. PubMed ID: 30647182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry.
    Mease PJ; Karki C; Liu M; Li Y; Gershenson B; Feng H; Hur P; Greenberg JD
    RMD Open; 2019; 5(1):e000880. PubMed ID: 31168408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
    Martinez-Cutillas J; Alerany-Pardo C; Borrás-Blasco J; Broto-Sumalla A; Burgos-SanJosé A; Climent-Bolta C; Escudero-Vilaplana V; Fernández-Fuente MA; Ferrit-Martin M; Gómez-Germá P; Martínez-Sesmero JM; Mayorga-Pérez J; Menchén-Viso B; Merino-Alonso J; Polache-Vengud J; Sánchez-Guerrero A
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):851-8. PubMed ID: 25972066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rheumatoid arthritis patients fulfilling Korean National Health Insurance reimbursement guidelines for anti-tumor necrosis factor-α treatment and comparison to other guidelines.
    Hur JW; Choe JY; Kim DW; Kim HA; Kim SH; Kim WU; Kim YS; Lee HS; Lee SH; Park SH; Park W; Park YB; Suh CH; Shim SC; Song YW; Yoon BY; Yu DY; Yoo DH
    Rheumatol Int; 2015 Nov; 35(11):1817-23. PubMed ID: 26342296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacist and physician satisfaction and rates of switching to preferred medications associated with an instant prior authorization program for proton pump inhibitors in the North Carolina Medicaid program.
    Jacobson Vann JC; Christofferson S; Humble CG; Wegner SE; Feaganes JR; Trygstad TK
    J Manag Care Pharm; 2010 May; 16(4):250-63. PubMed ID: 20433216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Profile of judicialization in access to antineoplastic drugs and their costs: a cross-sectional, descriptive study based on a set of all lawsuits filed between 2016 and 2018 in a state in the Northeast Region of Brazil.
    de Oliveira FHC; de Lorena Sobrinho JE; da Cruz Gouveia Mendes A; Gutman HMS; Filho GJ; Montarroyos UR
    BMC Public Health; 2022 Sep; 22(1):1824. PubMed ID: 36163021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dermatological guidelines for monitoring methotrexate treatment reduce drug-survival compared to rheumatological guidelines.
    Busger Op Vollenbroek FTM; Doggen CJM; Janssens RWA; Bernelot Moens HJ
    PLoS One; 2018; 13(3):e0194401. PubMed ID: 29570708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study.
    Kristensen LE; Englund M; Neovius M; Askling J; Jacobsson LT; Petersson IF
    Ann Rheum Dis; 2013 Oct; 72(10):1675-9. PubMed ID: 23148309
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible.
    Palsson O; Love TJ; Gunnarsdottir AI; Gunnarsson PS; Runarsdottir EE; Krogh NS; Gudbjornsson B
    RMD Open; 2019; 5(2):e000984. PubMed ID: 31413869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.